Evidence map›Paper›PMID 40121086›Full record

ArticleMethods in enzymology2025

CRISPRoff epigenome editing for programmable gene silencing in human cell lines and primary T cells.

Rithu K Pattali, Izaiah J Ornelas, Carolyn D Nguyen, Da Xu, Nikita S Divekar, NunezJames K Nuñez

Abstract read
In one paragraph

Article in Methods in enzymology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Clinical translation of epigenome editing technologies.Current opinion in biomedical engineering · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Rithu K PattaliDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, United States.
Izaiah J OrnelasDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, United States.
Carolyn D NguyenDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, United States.
Da XuDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, United States.
Nikita S DivekarDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, United States.
NunezJames K NuñezDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, United States; Chan Zuckerberg Biohub San Francisco, San Francisco, CA, United States. Electronic address: jamesnunez@berkeley.edu.

Funding

Mechanisms of epigenetic memory in human cellsR35GM155044 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI James Karlo Nunez · 2024 to 2026
$1.2M
NIGMS NIH HHS R35 GM155044
6 · The paper itself

Abstract

The advent of CRISPR-based technologies has enabled the rapid advancement of programmable gene manipulation in cells, tissues, and whole organisms. An emerging platform for targeted gene perturbation is epigenetic editing, the direct editing of chemical modifications on DNA and histones that ultimately results in repression or activation of the targeted gene. In contrast to CRISPR nucleases, epigenetic editors modulate gene expression without inducing DNA breaks or altering the genomic sequence of host cells. Recently, we developed the CRISPRoff epigenetic editing technology that simultaneously establishes DNA methylation and repressive histone modifications at targeted gene promoters. Transient expression of CRISPRoff and the accompanying single guide RNAs in mammalian cells results in transcriptional repression of targeted genes that is memorized heritably by cells through cell division and differentiation. Here, we describe our protocol for the delivery of CRISPRoff through plasmid DNA transfection, as well as the delivery of CRISPRoff mRNA, into transformed human cell lines and primary immune cells. We also provide guidance on evaluating target gene silencing and highlight key considerations when utilizing CRISPRoff for gene perturbations. Our protocols are broadly applicable to other CRISPR-based epigenetic editing technologies, as programmable genome manipulation tools continue to evolve rapidly.

Indexed as

CRISPR-Cas SystemsEpigenomeGene EditingGene SilencingT-LymphocytesCell LineDNA MethylationEpigenesis, GeneticEpigenome EditingHumansRNA, Guide, CRISPR-Cas SystemsTransfectionRNA, Guide, CRISPR-Cas SystemsCRISPRCRISPRoffDNA methylationepigenetic editingepigenetic inheritance

Identifiers

PMID40121086
PMCPMC12052198

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.